Lateral Flow Assays Market is projected to reach a valuation of US$ 6.9 billion by 2033

 The Lateral Flow Assays Market is expected to be worth US$ 4.3 billion in 2023, rising to US$ 6.9 billion by 2033. During the forecast period, lateral flow assay sales are expected to grow at a CAGR of 4.7%.


The market profited from the COVID-19 pandemic. The use of lateral flow test kits, which are smaller, portable, and easy to operate, can be more practical than sending patient samples to the lab. This makes them appealing for use in low- and middle-income nations, in countries implementing mass population screening programs, or for deployment outside of healthcare facilities.

To learn more about this report @ https://www.futuremarketinsights.com/reports/lateral-flow-assays-market

Although less accurate than PCR testing, lateral flow tests are nonetheless popular in nations without large laboratory infrastructure or skilled medical personnel to perform PCR tests due to their affordability, rapidity, and convenience of use.

The increasing prevalence of infectious diseases and the need for novel diagnostic techniques and efficient treatments to stop the rising death rate are the key factors propelling the expansion of the lateral flow assay market. The adoption of new labels, innovative signal enhancement techniques, improved quantification systems, and simultaneous detection are just a few of the significant advancements in LFA research that have occurred in recent years.

The expansion of the global market is anticipated to be aided by rising government involvement in containing infectious disease outbreaks and rising public awareness campaigns concerning the spread of infections.

Key Takeaways from Market Study

  • The increasing use of lateral flow kits and reagents for POC testing and the rising number of product launches by market participants are both responsible for the segment’s growth of 5.8%.
  • Infectious diseases emerged as the market segment’s leading indicators, driving the growth of 4.3%. It reduces the need for repeated patient visits and makes it easier to manage and contain infectious disease outbreaks quickly.
  • United States to contribute US$ 1.6 billion by 2033. The COVID-19 pandemic has raised public awareness and increased access to a variety of diagnostic tests which is predicted to stimulate substantial expansion.
  • In 2021, the United Kingdom has a market share of roughly 16.8% in Europe for lateral flow assays. The use of quick lateral flow tests for the detection of infection is strongly encouraged by the government, which has benefited the lateral flow assay market in the United Kingdom.
  • Due to different government initiatives, improving healthcare infrastructure, and rising demand for high-quality treatment at reasonable pricing, the China market is anticipated to grow at the rate of 9.3% in the coming years.

Competitive Landscape

Key players in the lateral flow assay market are expanding their market position through a variety of organic and inorganic tactics, including alliances, mergers and acquisitions, geographic growth, and strategic collaborations.

Key Players Include:

  • Abbott Laboratories
  • Becton, Dickinson and Company
  • Biomérieux SA
  • Bio-Rad Laboratories
  • Danaher Corporation
  • F Hoffmann-La Roche Ltd.
  • Merck
  • Quidel Corporation
  • Siemens Healthineers AG
  • Thermo Fisher Scientific Inc.

Latest Developments

  • In August 2021, Becton, Dickinson and Company got approval for an over-the-counter fast antigen test employing the Scanwell Health Mobile App.
  • In April 2021, USA Track & Field (USATF) and Becton, Dickinson and Company joined together to offer athletes using the B.D. veritor plus system quick COVID-19 testing.
  • In September 2020, Qiagen N.V. (Netherlands) acquired NeuMoDx Molecular, Inc. to diversify its line of diagnostics instruments and strengthen its position in the automated molecular testing industry.
  • In July 2020, Merck KGaA (Germany) announced plans to spend US$ 21 million to expand a new production facility in Buchs (Switzerland).

Key Segments Covered in the Market Report

By Application:

  • Clinical Testing
  • Veterinary Diagnostics
  • Food Safety & Environmental Testing
  • Drug Development & Quality Testing

By Technique:

  • Sandwich Assays
  • Competitive Assays
  • Multiplex Detection Assays
  • By Sample Type:
  • Blood Samples
  • Urine Samples
  • Saliva Samples
  • Others
  • By Type
  • Kits & Reagents
  • Lateral Flow Readers

By End User:

  • Hospitals & Clinics
  • Diagnostics Laboratories
  • Home Care Settings
  • Pharmaceuticals & Biotechnology Companies
  • Others

Comments

Post a Comment

Popular posts from this blog

Pet Diabetes Care Devices Market Report | Size, Growth, Demand, Scope and Forecast to 2032

  The global  Pet Diabetes Care Devices Market  is expected to grow at a  6.5%  CAGR, reaching  US$ 4 billion  by 2032, up from  US$ 2 billion  in 2021. “The number of pets with diabetes, the number of adopted pets, and the number of overweight pets are all driving the market forward.” Get Full Access @ https://www.futuremarketinsights.com/reports/pet-diabetes-care-devices-market The domestication of animals is leading to a lack of insulin production in them. The limited flow of glucose to the cell can be termed diabetes. This chronic disease is a major concern for pet owners and needs to be taken care of. This concern leads to the expansion of the pet diabetes care devices market. Devices like the alphatrak blood glucose meter are in use as they help the pet owners monitor the pet’s health. The increased number of people adopting pets and then domesticating them around in their households, treating and caring for them as f...
Read more

Human Immunodeficiency Virus Type 1 (HIV 1) Market Opportunity, Competitive Analysis, Future Prospects to 2033

Image
  The global Human Immunodeficiency Virus Type 1 (HIV 1) Market is predicted to exceed a remarkable valuation of US$ 34.83 Billion in 2023, with a compound annual rate of growth (CAGR) of 6% estimated from 2023 to 2033. The Institute for Health Metrics and Evaluation attributes the industry's growth to the soaring incidence rate of HIV-1 infection, which, unlike the deaths caused from this viral illness, has not updated substantially over time. Get Full Access @ https://www.futuremarketinsights.com/reports/human-immunodeficiency-virus-type-1-hiv1-market It affected approximately 37 million people worldwide. Furthermore, antiretroviral therapeutic interventions for disease management are only available to half of this population. HIV-1 is the more common of the two types of human immunodeficiency virus, accounting for approximately 96% of all infections globally. The prevalence of HIV is rising at an alarming rate. The World Health Organization (WHO) estimates that 33.0 million...
Read more

Clostridium Diagnostics Market in US is anticipated to secure a market value worth US$ 2.7 Billion by 2032 | FMI

Image
  The global Clostridium Diagnostics Market is expected to grow at a CAGR of 12.2% during the forecast period, from US$ 2.5 billion in 2022 to US$ 7.8 billion by 2032. The market grew at a CAGR of 13.6% between 2015 and 2021. The rising prevalence of clostridium-related diseases, as well as increased campaigns to educate people about the condition, are driving the market growth. To learn more about this report @ https://www.futuremarketinsights.com/reports/clostridium-diagnostics-market here has been an increased focus of players in the market to offer vaccines, which can augment the market size in the forecast period. For instance, in March 2022, Japan launched a new center, with a budget of US$ 1.6 Billion, to support vaccine and drug projects as a part of a larger scheme to tackle infectious diseases. SCARDA will be in charge of establishing a flagship R&D site for innovative collaborations and controlling funds for R&D projects. Awareness camp...
Read more